Shi LJ et al. 35 have suggested that the therapeutic effects of oxymatrine on hepatic steatosis in rats with high-fructose diet-induced fatty liver are partly due to up-regulation of the PPAR-α-mediated metabolic pathways. The gene discussed is PPARA; the disease is fatty liver disease.